CA2582385A1 - Formulations therapeutiques de traitement des affections rattachees a la proteine beta-amyloide - Google Patents

Formulations therapeutiques de traitement des affections rattachees a la proteine beta-amyloide Download PDF

Info

Publication number
CA2582385A1
CA2582385A1 CA002582385A CA2582385A CA2582385A1 CA 2582385 A1 CA2582385 A1 CA 2582385A1 CA 002582385 A CA002582385 A CA 002582385A CA 2582385 A CA2582385 A CA 2582385A CA 2582385 A1 CA2582385 A1 CA 2582385A1
Authority
CA
Canada
Prior art keywords
agent
foregoing
amyloid
pharmaceutical composition
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002582385A
Other languages
English (en)
Inventor
Francine Gervais
Francesco Bellini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bellus Health International Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/871,514 external-priority patent/US7414076B2/en
Priority claimed from US10/871,512 external-priority patent/US20050038000A1/en
Priority claimed from US10/871,549 external-priority patent/US20050142191A1/en
Priority claimed from US10/871,537 external-priority patent/US20050031651A1/en
Priority claimed from US10/871,365 external-priority patent/US7244764B2/en
Priority claimed from US10/871,543 external-priority patent/US7253306B2/en
Application filed by Individual filed Critical Individual
Publication of CA2582385A1 publication Critical patent/CA2582385A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention a trait à des procédés et des compositions pharmaceutiques pour le traitement de maladies associées au bêta-amyloïde, y compris la maladie d'Alzheimer. L'invention a trait, par exemple, à un procédé de traitement thérapeutique concomitant d'un sujet, comprenant l'administration d'une quantité efficace d'un premier agent et d'un deuxième agent, ledit premier agent traitant une maladie associée au bêta-amyloïde, la dégénérescence, ou la toxicité cellulaire; et ledit deuxième agent étant un médicament thérapeutique ou un supplément nutritif.
CA002582385A 2004-06-18 2005-06-17 Formulations therapeutiques de traitement des affections rattachees a la proteine beta-amyloide Abandoned CA2582385A1 (fr)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US87161304A 2004-06-18 2004-06-18
US10/871,365 2004-06-18
US10/871,514 US7414076B2 (en) 2003-06-23 2004-06-18 Methods and compositions for treating amyloid-related diseases
US10/871,512 US20050038000A1 (en) 2003-06-23 2004-06-18 Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases
US10/871,613 2004-06-18
US10/871,549 US20050142191A1 (en) 2003-06-23 2004-06-18 Pharmaceutical formulations of amyloid inhibiting compounds
US10/871,543 2004-06-18
US10/871,512 2004-06-18
US10/871,537 2004-06-18
US10/871,537 US20050031651A1 (en) 2002-12-24 2004-06-18 Therapeutic formulations for the treatment of beta-amyloid related diseases
US10/871,365 US7244764B2 (en) 2003-06-23 2004-06-18 Methods and compositions for treating amyloid-related diseases
US10/871,543 US7253306B2 (en) 2003-06-23 2004-06-18 Pharmaceutical drug candidates and methods for preparation thereof
US10/871,514 2004-06-18
US10/871,549 2004-06-18
PCT/IB2005/004199 WO2007049098A2 (fr) 2004-06-18 2005-06-17 Formulations therapeutiques pour le traitement de maladies associees au beta-amyloide

Publications (1)

Publication Number Publication Date
CA2582385A1 true CA2582385A1 (fr) 2005-12-18

Family

ID=37968188

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002582385A Abandoned CA2582385A1 (fr) 2004-06-18 2005-06-17 Formulations therapeutiques de traitement des affections rattachees a la proteine beta-amyloide

Country Status (4)

Country Link
EP (1) EP1841460A2 (fr)
JP (1) JP2008504372A (fr)
CA (1) CA2582385A1 (fr)
WO (1) WO2007049098A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010096925A1 (fr) * 2009-02-26 2010-09-02 Bellus Health (International) Limited Matériau comestible complété et/ou enrichi en homotaurine, procédés de préparation et utilisations

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3851447T3 (da) 2006-10-12 2023-12-04 Bellus Health Inc Fremgangsmåder, forbindelser, sammensætninger og vehikler til administration af 3-amino-1-propansulfonsyre
EP2349233A4 (fr) * 2008-10-09 2012-04-18 Waratah Pharmaceuticals Inc Utilisation de scyllo-inositols pour le traitement de troubles liés à la dégénérescence maculaire
EP2349988A4 (fr) * 2008-11-14 2012-05-02 Bellus Health Inc Sels nutritifs organiques, leurs procédés de préparation et leurs utilisations
WO2011011060A1 (fr) 2009-07-22 2011-01-27 Puretech Ventures Procédés et compositions de traitement de troubles, ceux-ci étant améliorés par l'activation du récepteur muscarinique
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
CA2777827C (fr) 2009-10-30 2020-08-18 Retrotope, Inc. Soulagement de troubles lies au stress oxydatif par des derives de pufa
KR102020611B1 (ko) 2011-04-26 2019-09-10 레트로토프 인코포레이티드 Ｐｕｆａ와 관련된 신경퇴행성 질환 및 근육 질환
AU2012249921B2 (en) 2011-04-26 2017-06-08 Biojiva Llc Oxidative retinal diseases
KR102020579B1 (ko) 2011-04-26 2019-09-10 레트로토프 인코포레이티드 에너지 프로세싱 손상 장애 및 미토콘드리아 결함
WO2012148929A2 (fr) 2011-04-26 2012-11-01 Retrotope, Inc. Troubles impliquant l'oxydation des acides gras polyinsaturés (pufa)
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
CN102793694B (zh) * 2012-08-14 2014-06-04 武汉华纳联合药业有限公司 3-氨基-1-丙烷磺酸及其衍生物在制备治疗脑卒中的药物中的应用
ES2871130T3 (es) 2015-11-23 2021-10-28 Retrotope Inc Marcado isotópico específico del sitio de sistemas de 1, 4-dieno
ITUA20161679A1 (it) * 2016-03-15 2017-09-15 Neuraxpharm Italy S P A Composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
JP7268049B2 (ja) 2018-03-08 2023-05-02 インサイト・コーポレイション ＰＩ３Ｋ－γ阻害剤としてのアミノピラジンジオール化合物
US20210228519A1 (en) * 2018-04-12 2021-07-29 The Regents Of The University Of California Methods for treating apoe4/4-associated disorders
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CA3180743A1 (fr) 2018-09-28 2020-04-02 Karuna Therapeutics, Inc. Composition comprenant de la xanomeline et du trospium pour le traitement de troubles ameliores par l'activation du recepteur muscarinique
EP4107163A1 (fr) 2020-02-21 2022-12-28 Retrotope, Inc. Procédés de modification isotopique d'acides gras polyinsaturés et leurs dérivés

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2395314A1 (fr) * 1999-12-23 2001-11-15 Neurochem, Inc. Composes et methodes permettant la modulation de l'angiopathie cerebrale amyloide
BR0317747A (pt) * 2002-12-24 2005-11-22 Neurochem Int Ltd Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010096925A1 (fr) * 2009-02-26 2010-09-02 Bellus Health (International) Limited Matériau comestible complété et/ou enrichi en homotaurine, procédés de préparation et utilisations

Also Published As

Publication number Publication date
EP1841460A2 (fr) 2007-10-10
JP2008504372A (ja) 2008-02-14
WO2007049098A3 (fr) 2007-10-04
WO2007049098A2 (fr) 2007-05-03

Similar Documents

Publication Publication Date Title
AU2003291910B2 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050031651A1 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
CA2582385A1 (fr) Formulations therapeutiques de traitement des affections rattachees a la proteine beta-amyloide
CN100571701C (zh) 治疗β淀粉样蛋白相关疾病的治疗性制品
JP4614460B2 (ja) シトステロール血症の処置のための置換アゼチジノン化合物の使用
US7244749B2 (en) Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases
US6472400B1 (en) Advanced gylcation end-product intermediaries and post-Amadori inhibition
JP2008514718A (ja) 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ
JP2000515526A (ja) Ｍｔｐ阻害剤と他のコレステロール低下薬を組合せて使用する、血清脂質レベルの降下方法
JP2004517919A (ja) 血管状態の処置のための心臓血管薬剤とステロール吸収インヒビターとの組み合わせ
US20050281868A1 (en) Transdermal delivery system for statin combination therapy
US6235706B1 (en) Combination therapy for reducing the risks associated with cardiovascular disease
CA2190107A1 (fr) Compositions pour le traitement de maladies inflammatoires chroniques
AU723315B2 (en) Combination therapy for reducing the risks associated with cardiovascular disease
JP2004517920A (ja) 血管状態を治療するためのステロール吸収阻害剤と血液調整剤との組合せ
US6251852B1 (en) Combination therapy for reducing the risks associated with cardiovascular disease
US20040220090A1 (en) Advanced glycation end-product intermediaries and post-amadori inhibition
HRP960341A2 (en) New methods of using n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters)
RO117297B1 (ro) Metoda de tratament a alcoolismului cronic sau a starilor datorate abuzului de alcool
WO2014087231A2 (fr) Composition pharmaceutique possédant une action neuro-protectrice, nootrope et anti-amnésique, et méthode de prévention et/ou de traitement d'états liés à une perturbation du flux sanguin dans le cerveau due à des maladies cérébrovasculaires et neurodégénératives
RU2703729C2 (ru) Комбинация и набор с анксиолитическим действием
UA82480C2 (uk) Застосування комбінації донепезилу та мемантину для лікування хвороби альцгеймера
JPH0311022A (ja) 薬剤組成物

Legal Events

Date Code Title Description
FZDE Dead